BR112015015202A2 - composição - Google Patents

composição

Info

Publication number
BR112015015202A2
BR112015015202A2 BR112015015202A BR112015015202A BR112015015202A2 BR 112015015202 A2 BR112015015202 A2 BR 112015015202A2 BR 112015015202 A BR112015015202 A BR 112015015202A BR 112015015202 A BR112015015202 A BR 112015015202A BR 112015015202 A2 BR112015015202 A2 BR 112015015202A2
Authority
BR
Brazil
Prior art keywords
composition
sulfbutyl
cabazitaxel
cyclodextrin
abstract
Prior art date
Application number
BR112015015202A
Other languages
English (en)
Other versions
BR112015015202B8 (pt
BR112015015202B1 (pt
Inventor
Pietrzynski Grzegorz
Patel Kishore
Alakhov Valery
Original Assignee
Pietrzynski Grzegorz
Patel Kishore
Supratek Pharma Inc
Alakhov Valery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pietrzynski Grzegorz, Patel Kishore, Supratek Pharma Inc, Alakhov Valery filed Critical Pietrzynski Grzegorz
Publication of BR112015015202A2 publication Critical patent/BR112015015202A2/pt
Publication of BR112015015202B1 publication Critical patent/BR112015015202B1/pt
Publication of BR112015015202B8 publication Critical patent/BR112015015202B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

resumo “composição” a presente invenção refere-se a uma composição que compreende (a) cabazitaxel e (b) sulfobutil-éter beta-ciclodextrina. tal composição exibe estabilidade inesperadamente desejável em meio aquoso, permitindo que dosagens terapêuticas do fármaco sejam administradas sem o uso nem de etanol nem de tensoativos.
BR112015015202A 2012-12-24 2013-12-23 Composição BR112015015202B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261848172P 2012-12-24 2012-12-24
US61/848,172 2012-12-24
PCT/IB2013/003255 WO2014122498A2 (en) 2012-12-24 2013-12-23 Cabazitaxel composition

Publications (3)

Publication Number Publication Date
BR112015015202A2 true BR112015015202A2 (pt) 2017-07-11
BR112015015202B1 BR112015015202B1 (pt) 2021-12-21
BR112015015202B8 BR112015015202B8 (pt) 2022-02-15

Family

ID=51300216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015202A BR112015015202B8 (pt) 2012-12-24 2013-12-23 Composição

Country Status (16)

Country Link
US (1) US9919053B2 (pt)
EP (1) EP2934593B1 (pt)
JP (1) JP6498610B2 (pt)
KR (1) KR102161866B1 (pt)
CN (1) CN105142671B (pt)
AU (1) AU2013377404B2 (pt)
BR (1) BR112015015202B8 (pt)
CA (1) CA2900508C (pt)
DK (1) DK2934593T3 (pt)
ES (1) ES2771423T3 (pt)
HU (1) HUE048505T2 (pt)
MX (1) MX371067B (pt)
PL (1) PL2934593T3 (pt)
PT (1) PT2934593T (pt)
RU (1) RU2678772C2 (pt)
WO (1) WO2014122498A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109731A1 (en) * 2016-12-16 2018-06-21 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical compositions of taxane and its derivatives
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技（广州）有限公司 一种注射用卡巴他赛组合物及其制备方法
CN113456586B (zh) * 2018-07-25 2022-06-10 比卡生物科技（广州）有限公司 一种注射用多西他赛组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443969A2 (en) * 2001-10-18 2004-08-11 Decode Genetics EHF Non-inclusion cyclodextrin complexes
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
EP1646445A4 (en) * 2003-07-18 2007-09-19 Baxter Int METHOD OF MANUFACTURING, USING AND COMPOSING SMALL BALLULAR PARTICLES PRODUCED BY CONTROLLED PHASE SEPARATION
BRPI0415637A (pt) * 2003-10-31 2006-12-12 Univ Kansas derivados de sulfoalquil éter-alquil éter ciclodextrina
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2013024495A1 (en) 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel

Also Published As

Publication number Publication date
PL2934593T3 (pl) 2020-05-18
CA2900508C (en) 2021-04-13
KR20150127035A (ko) 2015-11-16
CA2900508A1 (en) 2014-08-14
CN105142671B (zh) 2018-09-14
MX2015008225A (es) 2016-07-20
RU2678772C2 (ru) 2019-02-01
KR102161866B1 (ko) 2020-10-05
EP2934593A2 (en) 2015-10-28
AU2013377404A2 (en) 2015-08-27
MX371067B (es) 2020-01-15
WO2014122498A2 (en) 2014-08-14
DK2934593T3 (da) 2020-02-17
AU2013377404A1 (en) 2015-07-30
ES2771423T3 (es) 2020-07-06
AU2013377404B2 (en) 2018-08-23
US20150328321A1 (en) 2015-11-19
BR112015015202B8 (pt) 2022-02-15
RU2015130495A (ru) 2017-01-27
CN105142671A (zh) 2015-12-09
US9919053B2 (en) 2018-03-20
EP2934593B1 (en) 2020-02-05
BR112015015202B1 (pt) 2021-12-21
JP2016508138A (ja) 2016-03-17
EP2934593A4 (en) 2016-08-10
JP6498610B2 (ja) 2019-04-10
HUE048505T2 (hu) 2020-07-28
PT2934593T (pt) 2020-03-09
WO2014122498A3 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
MY196173A (en) Cot Modulators And Methods Of Use Thereof
CL2016000381A1 (es) Compuestos antivirales
CO6640250A2 (es) Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua
PH12015501354A1 (en) Antiviral compounds
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
AR082381A1 (es) Composicion acuosa que contiene bromhexina
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
MY179605A (en) Use of benzimidazole-proline derivatives
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
BR112013016590A2 (pt) uso de estabilizantes de glutamina
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
MX2011010547A (es) Composiciones farmaceuticas estables de diclofenaco.
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations
PH12016500142A1 (en) Vesicles
BR112015015202A2 (pt) composição
BR112014029874A8 (pt) composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica
BR112014031556A2 (pt) derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: SUPRATEK PHARMA INC. (CA)

B25G Requested change of headquarter approved

Owner name: SUPRATEK PHARMA INC. (CA)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2659 DE 21/12/2021 QUANTO AO ENDERECO.

B25A Requested transfer of rights approved

Owner name: SOFTKEMO PHARMA CORP. (CA)